ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
79 hedge funds and large institutions have $67M invested in Adaptimmune Therapeutics in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
1.78% less ownership
Funds ownership: 9.89% → 8.1% (-1.8%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
54% less capital invested
Capital invested by funds: $144M → $67M (-$77.1M)
Holders
79
Holding in Top 10
1
Calls
$24K
Puts
$9K
Top Buyers
| 1 | +$7.99M | |
| 2 | +$3.88M | |
| 3 | +$469K | |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$269K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$94.3K |
Top Sellers
| 1 | -$35.8M | |
| 2 | -$2.76M | |
| 3 | -$2.67M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$964K |
| 5 |
Millennium Management
New York
|
-$369K |